{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:33:25Z","timestamp":1792859605636,"version":"4.5.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["U24 AG082930"],"award-info":[{"award-number":["U24 AG082930"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1 AG077386"],"award-info":[{"award-number":["RF1 AG077386"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1 AG079397"],"award-info":[{"award-number":["RF1 AG079397"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1 AG69052"],"award-info":[{"award-number":["RF1 AG69052"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30 AG07247"],"award-info":[{"award-number":["P30 AG07247"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG059008"],"award-info":[{"award-number":["R01 AG059008"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG073212"],"award-info":[{"award-number":["R01 AG073212"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["T32 NS115704"],"award-info":[{"award-number":["T32 NS115704"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017312","name":"Lewy Body Dementia Association","doi-asserted-by":"publisher","award":["LBDA1811MS"],"award-info":[{"award-number":["LBDA1811MS"]}],"id":[{"id":"10.13039\/100017312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40120-024-00658-x","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T18:01:49Z","timestamp":1725732109000},"page":"1541-1557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Navigating the Landscape of Plasma Biomarkers in Alzheimer's Disease: Focus on Past, Present, and Future Clinical Applications"],"prefix":"10.1007","volume":"13","author":[{"given":"Sarrah E.","family":"Ankeny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia R.","family":"Bacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Decourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan N.","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7177-1185","authenticated-orcid":false,"given":"Michelle M.","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,7]]},"reference":[{"issue":"5","key":"658_CR1","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1002\/alz.13809","volume":"20","author":"Alzheimer\u2019s disease facts and figures","year":"2024","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2024;20(5):3708\u2013821.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"658_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34(7):939.","journal-title":"Neurology"},{"issue":"4","key":"658_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"658_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/archneur.1996.00550010045015","volume":"53","author":"LA Klatka","year":"1996","unstructured":"Klatka LA, Schiffer RB, Powers JM, Kazee AM. Incorrect diagnosis of Alzheimer\u2019s disease: a clinicopathologic study. Arch Neurol. 1996;53(1):35\u201342.","journal-title":"Arch Neurol"},{"issue":"4","key":"658_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","volume":"71","author":"TG Beach","year":"2012","unstructured":"Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005\u20132010. J Neuropathol Exp Neurol. 2012;71(4):266\u201373.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"658_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3233\/JAD-160821","volume":"56","author":"MN Sabbagh","year":"2017","unstructured":"Sabbagh MN, Sch\u00e4uble B, Anand K, Richards D, Murayama S, Akatsu H, et al. Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimer\u2019s disease. J Alzheimers Dis. 2017;56(2):441\u20136.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"658_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/jnen\/nlaa014","volume":"79","author":"K Gauthreaux","year":"2020","unstructured":"Gauthreaux K, Bonnett TA, Besser LM, Brenowitz WD, Teylan M, Mock C, et al. Concordance of clinical Alzheimer diagnosis and neuropathological features at autopsy. J Neuropathol Exp Neurol. 2020;79(5):465\u201373.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"13","key":"658_CR8","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286\u201394.","journal-title":"JAMA"},{"issue":"1","key":"658_CR9","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, Van Westen D, Jeromin A, et al. Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep. 2016;6(1):26801.","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"658_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40120-017-0073-9","volume":"6","author":"K Blennow","year":"2017","unstructured":"Blennow K. A review of fluid biomarkers for Alzheimer\u2019s disease: moving from CSF to blood. Neurol Ther. 2017;6(Suppl 1):15\u201324.","journal-title":"Neurol Ther"},{"key":"658_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/B978-0-12-804279-3.00002-2","volume":"146","author":"H Tumani","year":"2018","unstructured":"Tumani H, Huss A, Bachhuber F. The cerebrospinal fluid and barriers\u2013anatomic and physiologic considerations. Handb Clin Neurol. 2018;146:21\u201332.","journal-title":"Handb Clin Neurol"},{"issue":"11","key":"658_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049620","volume":"7","author":"T Kiko","year":"2012","unstructured":"Kiko T, Nakagawa K, Satoh A, Tsuduki T, Furukawa K, Arai H, et al. Amyloid \u03b2 levels in human red blood cells. PLoS One. 2012;7(11): e49620.","journal-title":"PLoS One"},{"issue":"1","key":"658_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.14336\/AD.2021.0529","volume":"13","author":"B Decourt","year":"2022","unstructured":"Decourt B, D\u2019Souza GX, Shi J, Ritter A, Suazo J, Sabbagh MN. The cause of Alzheimer\u2019s disease: the theory of multipathology convergence to chronic neuronal stress. Aging Dis. 2022;13(1):37\u201360.","journal-title":"Aging Dis"},{"issue":"8","key":"658_CR14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1586\/14737175.7.8.1021","volume":"7","author":"JA Sonnen","year":"2007","unstructured":"Sonnen JA, Keene CD, Montine KS, Li G, Peskind ER, Zhang J, et al. Biomarkers for Alzheimer\u2019s disease. Expert Rev Neurother. 2007;7(8):1021\u20138.","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"658_CR15","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1602\/neurorx.1.2.226","volume":"1","author":"MC Irizarry","year":"2004","unstructured":"Irizarry MC. Biomarkers of Alzheimer disease in plasma. NeuroRx. 2004;1(2):226\u201334.","journal-title":"NeuroRx"},{"issue":"2","key":"658_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/alzrt162","volume":"5","author":"JB Toledo","year":"2013","unstructured":"Toledo JB, Shaw LM, Trojanowski JQ. Plasma amyloid beta measurements-a desired but elusive Alzheimer\u2019s disease biomarker. Alzheimers Res Ther. 2013;5(2):8.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"658_CR17","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1212\/WNL.48.3.741","volume":"48","author":"T Kosaka","year":"1997","unstructured":"Kosaka T, Imagawa M, Seki K, Arai H, Sasaki H, Tsuji S, et al. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta 42 (43). Neurology. 1997;48(3):741\u20135.","journal-title":"Neurology"},{"issue":"8","key":"658_CR18","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease. Nat Med. 1996;2(8):864\u201370.","journal-title":"Nat Med"},{"issue":"1\u20132","key":"658_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0022-510X(96)00143-8","volume":"141","author":"A Tamaoka","year":"1996","unstructured":"Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, Komatsuzaki Y, et al. Amyloid \u03b2 protein in plasma from patients with sporadic Alzheimer\u2019s disease. J Neurol Sci. 1996;141(1\u20132):65\u20138.","journal-title":"J Neurol Sci"},{"issue":"1","key":"658_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/archneur.57.1.100","volume":"57","author":"PD Mehta","year":"2000","unstructured":"Mehta PD, Pirttil\u00e4 T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid \u03b2 proteins 1\u201340 and 1\u201342 in Alzheimer disease. Arch Neurol. 2000;57(1):100\u20135.","journal-title":"Arch Neurol"},{"issue":"9","key":"658_CR21","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1212\/01.WNL.0000091890.32140.8F","volume":"61","author":"R Mayeux","year":"2003","unstructured":"Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, et al. Plasma A\u03b240 and A\u03b242 and Alzheimer\u2019s disease: relation to age, mortality, and risk. Neurology. 2003;61(9):1185\u201390.","journal-title":"Neurology"},{"issue":"4","key":"658_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3233\/JAD-2005-8403","volume":"8","author":"D Galasko","year":"2006","unstructured":"Galasko D. Biomarkers for Alzheimer\u2019s disease\u2013clinical needs and application. J Alzheimers Dis. 2006;8(4):339\u201346.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"658_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1006\/bbrc.1995.2103","volume":"213","author":"M Chen","year":"1995","unstructured":"Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid \u03b2-peptide in human blood. Biochem Biophys Res Commun. 1995;213(1):96\u2013103.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"658_CR24","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","volume":"28","author":"DM Rissin","year":"2010","unstructured":"Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010;28(6):595\u20139.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"658_CR25","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.25334","volume":"84","author":"IM Verberk","year":"2018","unstructured":"Verberk IM, Slot RE, Verfaillie SC, Heijst H, Prins ND, van Berckel BN, et al. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol. 2018;84(5):648\u201358.","journal-title":"Ann Neurol"},{"issue":"12","key":"658_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028263","volume":"6","author":"H Zetterberg","year":"2011","unstructured":"Zetterberg H, M\u00f6rtberg E, Song L, Chang L, Provuncher GK, Patel PP, et al. Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid \u03b2 levels in humans. PLoS One. 2011;6(12): e28263.","journal-title":"PLoS One"},{"key":"658_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neulet.2014.04.041","volume":"573","author":"J Pannee","year":"2014","unstructured":"Pannee J, T\u00f6rnqvist U, Westerlund A, Ingelsson M, Lannfelt L, Brinkmalm G, et al. The amyloid-\u03b2 degradation pattern in plasma\u2014a possible tool for clinical trials in Alzheimer\u2019s disease. Neurosci Lett. 2014;573:7\u201312.","journal-title":"Neurosci Lett"},{"issue":"3","key":"658_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2183\/pjab.90.104","volume":"90","author":"N Kankeo","year":"2014","unstructured":"Kankeo N, Yamamoto R, Sato TA, Tanaka K. Identification and quantification of amyloid beta-related peptides in human plasma using matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry. Proc Jpn Acad Ser B Phys Biol Sci. 2014;90(3):104\u201317.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"8","key":"658_CR29","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841\u20139.","journal-title":"Alzheimers Dement"},{"issue":"7691","key":"658_CR30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor\u00e9 V, et al. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature. 2018;554(7691):249\u201354.","journal-title":"Nature"},{"issue":"11","key":"658_CR31","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Teunissen CE, Zetterberg H, Allu\u00e9 JA, Sarasa L, Eichenlaub U, et al. Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol. 2021;78(11):1375\u201382.","journal-title":"JAMA Neurol"},{"issue":"8","key":"658_CR32","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14(8):989\u201397.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"658_CR33","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772\u201381.","journal-title":"JAMA"},{"issue":"3","key":"658_CR34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387\u201397.","journal-title":"Nat Med"},{"issue":"4","key":"658_CR35","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/alz.12751","volume":"19","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist S, Stomrud E, Cullen N, Janelidze S, Manuilova E, Jethwa A, et al. An accurate fully automated panel of plasma biomarkers for Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(4):1204\u201315.","journal-title":"Alzheimers Dement"},{"key":"658_CR36","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13195-022-01116-2","volume":"14","author":"EN Wilson","year":"2022","unstructured":"Wilson EN, Young CB, Ramos Benitez J, Swarovski MS, Feinstein I, Vandijck M, et al. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14:172.","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"658_CR37","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jalz.2014.08.099","volume":"11","author":"SE O\u2019Bryant","year":"2015","unstructured":"O\u2019Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S, et al. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer\u2019s disease research. Alzheimers Dement. 2015;11(5):549\u201360.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"658_CR38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jalz.2016.09.014","volume":"13","author":"SE O\u2019Bryant","year":"2017","unstructured":"O\u2019Bryant SE, Mielke MM, Rissman RA, Lista S, Vanderstichele H, Zetterberg H, et al. Blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement. 2017;13(1):45\u201358.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"658_CR39","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/alz.12510","volume":"18","author":"IM Verberk","year":"2022","unstructured":"Verberk IM, Misdorp EO, Koelewijn J, Ball AJ, Blennow K, Dage JL, et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease\u2013related blood-based biomarkers: results from the Standardization of Alzheimer\u2019s Blood Biomarkers (SABB) working group. Alzheimers Dement. 2022;18(8):1484\u201397.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"658_CR40","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/medicina58070952","volume":"58","author":"J Cummings","year":"2022","unstructured":"Cummings J, Kinney J. Biomarkers for Alzheimer\u2019s Disease: context of use, qualification, and roadmap for clinical implementation. Medicina. 2022;58(7):952.","journal-title":"Medicina"},{"key":"658_CR41","unstructured":"FDA. Laboratory developed tests [Internet]. FDA; 2024 [cited 2024 May 30]. Laboratory Developed Tests. Available from: https:\/\/www.fda.gov\/medical-devices\/in-vitro-diagnostics\/laboratory-developed-tests"},{"issue":"12","key":"658_CR42","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1002\/alz.13455","volume":"19","author":"K Blennow","year":"2023","unstructured":"Blennow K, Galasko D, Perneczky R, Quevenco F, van der Flier WM, Akinwonmi A, et al. The potential clinical value of plasma biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(12):5805\u201316.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"658_CR43","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ, Barth\u00e9lemy NR, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain. 2023;146(4):1592\u2013601.","journal-title":"Brain"},{"issue":"12","key":"658_CR44","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2022;18(12):2669\u201386.","journal-title":"Alzheimers Dement"},{"issue":"17","key":"658_CR45","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647\u201359.","journal-title":"Neurology"},{"issue":"1","key":"658_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12545","volume":"16","author":"DJ Figdore","year":"2024","unstructured":"Figdore DJ, Wiste HJ, Bornhorst JA, Bateman RJ, Li Y, Graff-Radford J, et al. Performance of the Lumipulse plasma A\u03b242\/40 and pTau181 immunoassays in the detection of amyloid pathology. Alzheimers Dement (Amst). 2024;16(1): e12545.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"12","key":"658_CR47","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28(12):2555\u201362.","journal-title":"Nat Med"},{"issue":"4","key":"658_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12508","volume":"15","author":"I Suridjan","year":"2023","unstructured":"Suridjan I, van der Flier WM, Monsch AU, Burnie N, Baldor R, Sabbagh M, et al. Blood-based biomarkers in Alzheimer\u2019s disease: future directions for implementation. Alzheimers Dement (Amst). 2023;15(4): e12508.","journal-title":"Alzheimers Dement (Amst)"},{"key":"658_CR49","doi-asserted-by":"crossref","unstructured":"Cheng YW, Lin YJ, Lin YS, Hong WP, Kuan YC, Wu KY, et al. Application of blood-based biomarkers of Alzheimer\u2019s disease in clinical practice: recommendations from Taiwan Dementia Society. J Formos Med Assoc. 2024 Jan 30 [cited 2024 May 30]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0929664624000512.","DOI":"10.1016\/j.jfma.2024.01.018"},{"issue":"3","key":"658_CR50","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26(3):379\u201386.","journal-title":"Nat Med"},{"issue":"5","key":"658_CR51","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422\u201333.","journal-title":"Lancet Neurol"},{"issue":"7","key":"658_CR52","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke MM, Dage JL, Frank RD, Algeciras-Schimnich A, Knopman DS, Lowe VJ, et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022;28(7):1398\u2013405.","journal-title":"Nat Med"},{"issue":"9","key":"658_CR53","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie RL, Strom A, Fonseca C, Iaccarino L, Wolf A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20(9):739\u201352.","journal-title":"Lancet Neurol"},{"issue":"3","key":"658_CR54","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 2024;81(3):255\u201363.","journal-title":"JAMA Neurol"},{"issue":"6","key":"658_CR55","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"issue":"1","key":"658_CR56","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","volume":"91","author":"M Bacioglu","year":"2016","unstructured":"Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron. 2016;91(1):56\u201366.","journal-title":"Neuron"},{"issue":"1","key":"658_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuron.2016.06.030","volume":"91","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H. Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration. Neuron. 2016;91(1):1\u20133.","journal-title":"Neuron"},{"issue":"10","key":"658_CR58","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.15252\/emmm.201606540","volume":"8","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, et al. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer\u2019s disease. EMBO Mol Med. 2016;8(10):1184\u201396.","journal-title":"EMBO Mol Med"},{"key":"658_CR59","doi-asserted-by":"crossref","unstructured":"Mattsson N, Andreasson U, Zetterberg H. Blennow K, for the Alzheimer\u2019s Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557\u201366.","DOI":"10.1001\/jamaneurol.2016.6117"},{"issue":"2","key":"658_CR60","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med. 2019;25(2):277\u201383.","journal-title":"Nat Med"},{"issue":"12","key":"658_CR61","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/jnnp-2020-325537","volume":"92","author":"BS Rauchmann","year":"2021","unstructured":"Rauchmann BS, Schneider-Axmann T, Perneczky R. Associations of longitudinal plasma p-tau181 and NfL with tau-PET, A\u03b2-PET and cognition. J Neurol Neurosurg Psychiatry. 2021;92(12):1289\u201395.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"13","key":"658_CR62","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","volume":"87","author":"JD Rohrer","year":"2016","unstructured":"Rohrer JD, Woollacott IO, Dick KM, Brotherhood E, Gordon E, Fellows A, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87(13):1329\u201336.","journal-title":"Neurology"},{"issue":"2","key":"658_CR63","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/jnnp-2018-318704","volume":"90","author":"F Verde","year":"2019","unstructured":"Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(2):157\u201364.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"658_CR64","unstructured":"Eisai Inc. and Biogen. Leqembi (lecanemab-irmb) prescribing information. Eisai Inc. and Biogen; 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761269s000lbl.pdf."},{"key":"658_CR65","unstructured":"Eli Lilly and Company. Kisunla (donanemab-azbt) prescribing information. Eli Lilly and Company; 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761248s000lbl.pdf."},{"issue":"6","key":"658_CR66","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/alz.12466","volume":"18","author":"JA Syrjanen","year":"2022","unstructured":"Syrjanen JA, Campbell MR, Algeciras-Schimnich A, Vemuri P, Graff-Radford J, Machulda MM, et al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. 2022;18(6):1128\u201340.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"658_CR67","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","volume":"80","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Barth\u00e9lemy NR, He Y, Bateman RJ, Hansson O. Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios. JAMA Neurol. 2023;80(5):516\u201322.","journal-title":"JAMA Neurol"},{"issue":"4","key":"658_CR68","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","volume":"19","author":"A Pichet-Binette","year":"2023","unstructured":"Pichet-Binette A, Janelidze S, Cullen N, Dage JL, Bateman RJ, Zetterberg H, et al. Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 2023;19(4):1403\u201314.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"658_CR69","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/acn3.50972","volume":"7","author":"A Manouchehrinia","year":"2020","unstructured":"Manouchehrinia A, Piehl F, Hillert J, Kuhle J, Alfredsson L, Olsson T, et al. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Ann Clin Transl Neurol. 2020;7(1):139\u201343.","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"658_CR70","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006379","volume":"2","author":"T Saido","year":"2012","unstructured":"Saido T, Leissring MA. Proteolytic degradation of amyloid \u03b2-protein. Cold Spring Harb Perspect Med. 2012;2(6): a006379.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"658_CR71","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaneurol.2023.4719","volume":"81","author":"WS Brum","year":"2024","unstructured":"Brum WS, Docherty KF, Ashton NJ, Zetterberg H, Hansson O, McMurray JJ, et al. Effect of neprilysin inhibition on Alzheimer disease plasma biomarkers: a secondary analysis of a randomized clinical trial. JAMA Neurol. 2024;81(2):197\u2013200.","journal-title":"JAMA Neurol"},{"issue":"8","key":"658_CR72","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41582-024-00989-1","volume":"20","author":"MM Mielke","year":"2024","unstructured":"Mielke MM, Fowler NR. Alzheimer disease blood biomarkers: considerations for population-level use. Nat Rev Neurol. 2024;20(8):495\u2013504.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"658_CR73","first-page":"569","volume":"9","author":"D Angioni","year":"2022","unstructured":"Angioni D, Delrieu J, Hansson O, Fillit H, Aisen P, Cummings J, et al. Blood biomarkers from research use to clinical practice: what must be done? A report from the EU\/US CTAD Task Force. J Prev Alzheimers Dis. 2022;9(4):569\u201379.","journal-title":"J Prev Alzheimers Dis"},{"issue":"8","key":"658_CR74","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/s43587-022-00269-x","volume":"2","author":"H Hampel","year":"2022","unstructured":"Hampel H, Au R, Mattke S, van der Flier WM, Aisen P, Apostolova L, et al. Designing the next-generation clinical care pathway for Alzheimer\u2019s disease. Nat Aging. 2022;2(8):692\u2013703.","journal-title":"Nat Aging"},{"issue":"2","key":"658_CR75","first-page":"27-9","volume":"23","author":"J Pleen","year":"2024","unstructured":"Pleen J, Camerucci E, Al-Sabbagh M, Cunningham K. Blood-based biomarkers in Alzheimer disease: clinical implementation and limitations. Pract Neurol. 2024;23(2):27-9\u201335-9.","journal-title":"Pract Neurol."},{"issue":"6","key":"658_CR76","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s12264-022-00836-7","volume":"38","author":"S Huang","year":"2022","unstructured":"Huang S, Wang YJ, Guo J. Biofluid biomarkers of Alzheimer\u2019s disease: progress, problems, and perspectives. Neurosci Bull. 2022;38(6):677\u201391.","journal-title":"Neurosci Bull"},{"issue":"5","key":"658_CR77","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 2021;141(5):709\u201324.","journal-title":"Acta Neuropathol"},{"issue":"9","key":"658_CR78","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","volume":"78","author":"MM Mielke","year":"2021","unstructured":"Mielke MM, Frank RD, Dage JL, Jeromin A, Ashton NJ, Blennow K, et al. Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol. 2021;78(9):1108\u201317.","journal-title":"JAMA Neurol"},{"issue":"1","key":"658_CR79","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1038\/s41467-024-46876-7","volume":"15","author":"PR Kac","year":"2024","unstructured":"Kac PR, Gonz\u00e1lez-Ortiz F, Emer\u0161i\u010d A, Dulewicz M, Koutarapu S, Turton M, et al. Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer\u2019s disease neuropathology. Nat Commun. 2024;15(1):2615.","journal-title":"Nat Commun"},{"issue":"1","key":"658_CR80","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13024-023-00605-8","volume":"18","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz F, Kac PR, Brum WS, Zetterberg H, Blennow K, Karikari TK. Plasma phospho-tau in Alzheimer\u2019s disease: towards diagnostic and therapeutic trial applications. Mol Neurodegen. 2023;18(1):18.","journal-title":"Mol Neurodegen"},{"key":"658_CR81","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M, Salvad\u00f3 G, Ortiz-Romero P, Montoliu-Gaya L, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28:1797\u2013801.","journal-title":"Nat Med"},{"issue":"17","key":"658_CR82","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1212\/WNL.0000000000004569","volume":"89","author":"KB Casaletto","year":"2017","unstructured":"Casaletto KB, Elahi FM, Bettcher BM, Neuhaus J, Bendlin BB, Asthana S, et al. Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers. Neurology. 2017;89(17):1782\u20138.","journal-title":"Neurology"},{"issue":"9","key":"658_CR83","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1212\/WNL.0000000000002423","volume":"86","author":"H Wellington","year":"2016","unstructured":"Wellington H, Paterson RW, Portelius E, T\u00f6rnqvist U, Magdalinou N, Fox NC, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86(9):829\u201335.","journal-title":"Neurology"},{"issue":"12","key":"658_CR84","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jalz.2015.05.012","volume":"11","author":"A De Vos","year":"2015","unstructured":"De Vos A, Jacobs D, Struyfs H, Fransen E, Andersson K, Portelius E, et al. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer\u2019s disease. Alzheimers Dement. 2015;11(12):1461\u20139.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"658_CR85","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1096\/fj.201600816R","volume":"30","author":"E Goetzl","year":"2016","unstructured":"Goetzl E, Kapogiannis D, Schwartz J, Lobach I, Goetzl L, Abner EL, et al. Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer\u2019s disease. FASEB J. 2016;30(12):4141\u20138.","journal-title":"FASEB J"},{"issue":"1","key":"658_CR86","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/alz.12166","volume":"17","author":"L Jia","year":"2021","unstructured":"Jia L, Zhu M, Kong C, Pang Y, Zhang H, Qiu Q, et al. Blood neuro-exosomal synaptic proteins predict Alzheimer\u2019s disease at the asymptomatic stage. Alzheimers Dement. 2021;17(1):49\u201360.","journal-title":"Alzheimers Dement"},{"issue":"21","key":"658_CR87","doi-asserted-by":"publisher","first-page":"e2065","DOI":"10.1212\/WNL.0000000000012853","volume":"97","author":"M Mil\u00e0-Alom\u00e0","year":"2021","unstructured":"Mil\u00e0-Alom\u00e0 M, Brinkmalm A, Ashton NJ, Kvartsberg H, Shekari M, Operto G, et al. CSF synaptic biomarkers in the preclinical stage of Alzheimer disease and their association with MRI and PET: a cross-sectional study. Neurology. 2021;97(21):e2065\u201378.","journal-title":"Neurology"},{"issue":"1","key":"658_CR88","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jalz.2018.08.006","volume":"15","author":"\u00c5 Sandelius","year":"2019","unstructured":"Sandelius \u00c5, Portelius E, K\u00e4ll\u00e9n \u00c5, Zetterberg H, Rot U, Olsson B, et al. Elevated CSF GAP-43 is Alzheimer\u2019s disease specific and associated with tau and amyloid pathology. Alzheimers Dement. 2019;15(1):55\u201364.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"658_CR89","doi-asserted-by":"publisher","first-page":"e953","DOI":"10.1212\/WNL.0000000000010131","volume":"95","author":"M Tible","year":"2020","unstructured":"Tible M, Sandelius \u00c5, H\u00f6glund K, Brinkmalm A, Cognat E, Dumurgier J, et al. Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. Neurology. 2020;95(8):e953\u201361.","journal-title":"Neurology"},{"issue":"2","key":"658_CR90","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/jnc.13399","volume":"136","author":"A Ishiki","year":"2016","unstructured":"Ishiki A, Kamada M, Kawamura Y, Terao C, Shimoda F, Tomita N, et al. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer\u2019s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. J Neurochem. 2016;136(2):258\u201361.","journal-title":"J Neurochem"},{"issue":"1","key":"658_CR91","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12291","volume":"14","author":"D Shir","year":"2022","unstructured":"Shir D, Graff-Radford J, Hofrenning EI, Lesnick TG, Przybelski SA, Lowe VJ, et al. Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer\u2019s disease and vascular pathology. Alzheimers Dement (Amst). 2022;14(1): e12291.","journal-title":"Alzheimers Dement (Amst)"},{"key":"658_CR92","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.neurobiolaging.2020.07.009","volume":"96","author":"A Vergallo","year":"2020","unstructured":"Vergallo A, Lista S, Lemercier P, Chiesa PA, Zetterberg H, Blennow K, et al. Association of plasma YKL-40 with brain amyloid-\u03b2 levels, memory performance, and sex in subjective memory complainers. Neurobiol Aging. 2020;96:22\u201332.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"658_CR93","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12974-019-1531-3","volume":"16","author":"A Villar-Piqu\u00e9","year":"2019","unstructured":"Villar-Piqu\u00e9 A, Schmitz M, Hermann P, Goebel S, Bunck T, Varges D, et al. Plasma YKL-40 in the spectrum of neurodegenerative dementia. J Neuroinflamm. 2019;16(1):145.","journal-title":"J Neuroinflamm"},{"issue":"1","key":"658_CR94","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/medicina58010060","volume":"58","author":"I Mavroudis","year":"2021","unstructured":"Mavroudis I, Chowdhury R, Petridis F, Karantali E, Chatzikonstantinou S, Balmus IM, et al. YKL-40 as a potential biomarker for the differential diagnosis of Alzheimer\u2019s disease. Medicina. 2021;58(1):60.","journal-title":"Medicina"},{"issue":"4","key":"658_CR95","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208075","volume":"102","author":"MP Pase","year":"2024","unstructured":"Pase MP, Himali JJ, Puerta R, Beiser AS, Gonzales MM, Satizabal CL, et al. Association of plasma YKL-40 with MRI, CSF, and cognitive markers of brain health and dementia. Neurology. 2024;102(4): e208075.","journal-title":"Neurology"},{"issue":"1","key":"658_CR96","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13195-022-01118-0","volume":"15","author":"F Brosseron","year":"2023","unstructured":"Brosseron F, Maass A, Kleineidam L, Ravichandran KA, Kolbe CC, Wolfsgruber S, et al. Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer\u2019s disease: results from the DELCODE study. Alzheimers Res Ther. 2023;15(1):13.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"658_CR97","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13024-018-0247-7","volume":"13","author":"L Zhong","year":"2018","unstructured":"Zhong L, Wang Z, Wang D, Wang Z, Martens YA, Wu L, et al. Amyloid-beta modulates microglial responses by binding to the triggering receptor expressed on myeloid cells 2 (TREM2). Mol Neurodegen. 2018;13(1):15.","journal-title":"Mol Neurodegen"},{"issue":"369","key":"658_CR98","doi-asserted-by":"publisher","first-page":"369ra178","DOI":"10.1126\/scitranslmed.aag1767","volume":"8","author":"M Su\u00e1rez-Calvet","year":"2016","unstructured":"Su\u00e1rez-Calvet M, Araque Caballero M\u00c1, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, et al. Early changes in CSF sTREM2 in dominantly inherited Alzheimer\u2019s disease occur after amyloid deposition and neuronal injury. Sci Transl Med. 2016;8(369):369ra178.","journal-title":"Sci Transl Med."},{"issue":"11","key":"658_CR99","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1093\/brain\/awn217","volume":"131","author":"L Piccio","year":"2008","unstructured":"Piccio L, Buonsanti C, Cella M, Tassi I, Schmidt RE, Fenoglio C, et al. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain. 2008;131(11):3081\u201391.","journal-title":"Brain"},{"issue":"1","key":"658_CR100","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/ana.25385","volume":"85","author":"T Ohara","year":"2019","unstructured":"Ohara T, Hata J, Tanaka M, Honda T, Yamakage H, Yoshida D, et al. Serum soluble triggering receptor expressed on myeloid cells 2 as a biomarker for incident dementia: the Hisayama study. Ann Neurol. 2019;85(1):47\u201358.","journal-title":"Ann Neurol"},{"issue":"24","key":"658_CR101","doi-asserted-by":"publisher","DOI":"10.1172\/JCI158708","volume":"132","author":"A Zhao","year":"2022","unstructured":"Zhao A, Jiao Y, Ye G, Kang W, Tan L, Li Y, et al. Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer\u2019s disease. J Clin Invest. 2022;132(24): e158708.","journal-title":"J Clin Invest"},{"issue":"4","key":"658_CR102","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3390\/ijms19041057","volume":"19","author":"DH Kong","year":"2018","unstructured":"Kong DH, Kim YK, Kim MR, Jang JH, Lee S. Emerging roles of vascular cell adhesion molecule-1 (VCAM-1) in immunological disorders and cancer. Int J Mol Sci. 2018;19(4):1057.","journal-title":"Int J Mol Sci"},{"key":"658_CR103","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3389\/fphar.2019.01251","volume":"10","author":"N M\u00fcller","year":"2019","unstructured":"M\u00fcller N. The role of intercellular adhesion molecule-1 in the pathogenesis of psychiatric disorders. Front Pharmacol. 2019;10:1251.","journal-title":"Front Pharmacol"},{"issue":"9","key":"658_CR104","doi-asserted-by":"publisher","first-page":"e867","DOI":"10.1212\/WNL.0000000000006082","volume":"91","author":"S Janelidze","year":"2018","unstructured":"Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018;91(9):e867\u201377.","journal-title":"Neurology"},{"issue":"4","key":"658_CR105","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/0891988704269822","volume":"17","author":"M Rentzos","year":"2004","unstructured":"Rentzos M, Michalopoulou M, Nikolaou C, Cambouri C, Rombos A, Dimitrakopoulos A, et al. Serum levels of soluble intercellular adhesion molecule-1 and soluble endothelial leukocyte adhesion molecule-1 in Alzheimer\u2019s disease. J Geriatr Psychiatry Neurol. 2004;17(4):225\u201331.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"1\u20132","key":"658_CR106","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jns.2008.05.020","volume":"272","author":"G Zuliani","year":"2008","unstructured":"Zuliani G, Cavalieri M, Galvani M, Passaro A, Munari MR, Bosi C, et al. Markers of endothelial dysfunction in older subjects with late onset Alzheimer\u2019s disease or vascular dementia. J Neurol Sci. 2008;272(1\u20132):164\u201370.","journal-title":"J Neurol Sci"},{"issue":"2","key":"658_CR107","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00415-012-6648-6","volume":"260","author":"MT Pellecchia","year":"2013","unstructured":"Pellecchia MT, Santangelo G, Picillo M, Pivonello R, Longo K, Pivonello C, et al. Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson\u2019s disease patients. J Neurol. 2013;260(2):438\u201344.","journal-title":"J Neurol"},{"issue":"4","key":"658_CR108","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/ana.22271","volume":"69","author":"AS Chen-Plotkin","year":"2011","unstructured":"Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol. 2011;69(4):655\u201363.","journal-title":"Ann Neurol"},{"issue":"5","key":"658_CR109","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/acn3.299","volume":"3","author":"NS Lim","year":"2016","unstructured":"Lim NS, Swanson CR, Cherng HR, Unger TL, Xie SX, Weintraub D, et al. Plasma EGF and cognitive decline in Parkinson\u2019s disease and Alzheimer\u2019s disease. Ann Clin Transl Neurol. 2016;3(5):346\u201355.","journal-title":"Ann Clin Transl Neurol"},{"issue":"11","key":"658_CR110","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm1653","volume":"13","author":"S Ray","year":"2007","unstructured":"Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer\u2019s diagnosis based on plasma signaling proteins. Nat Med. 2007;13(11):1359\u201362.","journal-title":"Nat Med"},{"issue":"3","key":"658_CR111","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10456-008-9114-4","volume":"11","author":"D Ribatti","year":"2008","unstructured":"Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis. 2008;11(3):215\u201321.","journal-title":"Angiogenesis"},{"issue":"5","key":"658_CR112","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/acn3.763","volume":"6","author":"O Hansson","year":"2019","unstructured":"Hansson O, Santillo AF, Meeter LH, Nilsson K, Landqvist Wald\u00f6 M, Nilsson C, et al. CSF placental growth factor\u2014a novel candidate biomarker of frontotemporal dementia. Ann Clin Transl Neurol. 2019;6(5):863\u201372.","journal-title":"Ann Clin Transl Neurol"},{"issue":"21","key":"658_CR113","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1212\/WNL.0000000000002151","volume":"85","author":"S Janelidze","year":"2015","unstructured":"Janelidze S, Lindqvist D, Francardo V, Hall S, Zetterberg H, Blennow K, et al. Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology. 2015;85(21):1834\u201342.","journal-title":"Neurology"},{"issue":"3","key":"658_CR114","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3233\/JAD-230811","volume":"97","author":"LY Wu","year":"2024","unstructured":"Wu LY, Chong JR, Chong J, Hilal S, Venketasubramanian N, Tan BW, et al. Serum placental growth factor as a marker of cerebrovascular disease burden in Alzheimer\u2019s disease. J Alzheimers Dis. 2024;97(3):1289\u201398.","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"658_CR115","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1002\/alz.12974","volume":"19","author":"JD Hinman","year":"2023","unstructured":"Hinman JD, Elahi F, Chong D, Radabaugh H, Ferguson A, Maillard P, et al. Placental growth factor as a sensitive biomarker for vascular cognitive impairment. Alzheimers Dement. 2023;19(8):3519\u201327.","journal-title":"Alzheimers Dement"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00658-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00658-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00658-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T13:18:05Z","timestamp":1730899085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00658-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,7]]},"references-count":115,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["658"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00658-x","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,7]]},"assertion":[{"value":"2 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Mielke has served on scientific advisory boards and\/or has consulted for Acadia, Biogen, Eisai, LabCorp, Lilly, Merck, PeerView Institute, Novo Nordisk, Roche, Siemens Healthineers and Sunbird Bio. Dr. Sabbagh is an Editor-in-Chief of <i>Neurology and Therapy<\/i>. Dr. Sabbagh was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Dr. Sabbagh has served as the Board of Directors for EIP Pharma\/CervoMed and consulted for Roche-Genentech, Eisai, Lilly, NeuroTherapia, Signant Health, Novo Nordisk, Anavex, Cognito Therapeutics, GSK, Abbvie, Lighthouse Pharmaceuticals, Alzheon, and Athira. All other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This review is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}